Developer docs
API playgroundTry for free, no card

Search company profiles

sigma-tau

Full company profile

uuid000fc26

Namestring
sigma-tau
Legal namestring
Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
Websiteurl
sigma-tau.it
Company typeenum
Private
Founded yearint
1957
Descriptiontext

Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. was an Italian pharmaceutical group that manufactured and marketed medicinal specialties. Founded in 1957 by Claudio Cavazza, the company operated as a vertically integrated pharmaceutical business organized under Italian law as a società per azioni (S.p.A.), with a workforce of 5,001–10,000 employees. Its core function was the production and distribution of pharmaceutical products under Italian Marketing Authorizations (Autorizzazione all'Immissione in Commercio, AIC), serving the Italian and broader European pharmaceutical market. The company held proprietary marketing authorizations across a portfolio of medicinal specialties accumulated over approximately six decades of operation.

Following decades of independent operation, Sigma-Tau ceased to exist as a separate legal entity on August 1, 2017, through a three-way merger by incorporation into Alfasigma S.p.A., alongside Alfa Wassermann S.p.A. and Biofutura Pharma S.p.A. Alfasigma, headquartered at Via Ragazzi del '99, 5 – 40133 Bologna, Italy (P.IVA 03432221202), assumed all assets, liabilities, and marketing authorizations of the merged entities. The legacy sigma-tau.it domain was retained only to complete the regulatory transfer of AIC holders and was redirected to the Alfasigma corporate site. The legal and administrative headquarters formerly associated with Sigma-Tau in Bologna were transferred to Alfasigma upon completion of the merger.

The company generated revenue through pharmaceutical manufacturing and distribution of its proprietary medicinal specialty portfolio, though no product names, pricing models, distribution channel details, or revenue figures are disclosed in the available source data. All revenue-generating operations and product portfolios are now consolidated under Alfasigma S.p.A., making Sigma-Tau's independent operating history effectively concluded.

Short descriptiontext

Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. was an Italian pharmaceutical group founded in 1957 that manufactured and marketed medicinal specialties. The company ceased independent operations on August 1, 2017, when it merged by incorporation into Alfasigma S.p.A.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
5,001–10,000
akta.pro rankint
HeadquartersVico Nel Lazio, Italy
HQ citystring
Vico Nel Lazio
HQ countrystring
Italy
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical manufacturing, medicinal specialties, drug distribution, prescription pharmaceuticals, pharmaceutical products
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing32541
  • Medicinal and Botanical Manufacturing325411
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pharmaceutical Manufacturing
Social media profiles1 record
Cost components6 values
Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. was an Italian pharmaceutical company that manufactured and marketed medicinal specialties (specialità medicinali) and pharmaceutical products under registered Marketing Authorizations (AIC). All products, assets, and Marketing Authorizations were transferred to Alfasigma S.p.A. upon the merger effective August 1, 2017.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. was an Italian pharmaceutical company. As of August 1, 2017, it merged by absorption into Alfasigma S.p.A. along with Alfa Wassermann S.p.A. and Biofutura Pharma S.p.A. The company was involved in the production and distribution of medicinal specialties (specialità medicinali). This legacy page is maintained only to complete the transfer of marketing authorization holders (AIC) to Alfasigma. No specific product names are detailed in the available source data.

Recent move2 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight1 record

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Alfasigma is the Italian specialty-pharma group that absorbed Sigma-Tau by merger on 1 August 2017 along with Alfa Wassermann and Biofutura Pharma. It is now the direct continuation of Sigma-Tau's medicinal specialty business and is headquartered in Bologna.

TypeDirect peer
Description

Florence-based privately held Italian pharmaceutical group of comparable mid-large size focused on branded specialty therapeutics, prescription drugs and consumer health - structurally analogous to Sigma-Tau's Italian pharma house positioning.

TypeDirect peer
Description

Privately held Italian specialty pharma headquartered in Parma with comparable scale, manufacturing medicinal products for respiratory, neonatology and rare disease - a closely comparable Italian branded-pharma peer to Sigma-Tau.

TypeDirect peer
Description

Listed Italian mid-cap specialty pharmaceutical company headquartered in Milan, focused on branded prescription drugs in cardiovascular, urology and rare diseases - directly comparable in scale, geography and product mix to Sigma-Tau's medicinal specialty business.

TypeDirect peer
Description

Italian privately held pharmaceutical group (Bresso/Milan) producing and marketing branded medicinal specialties across respiratory, pain and CNS - comparable mid-sized Italian specialty pharma peer to Sigma-Tau.

TypeDirect peer
Description

Angelini group's pharma division, an Italian privately held branded-pharma manufacturer of medicinal specialties (CNS, pain, infectious disease) - similar scope, scale and Italian distribution model to Sigma-Tau.

TypeDirect peer
Description

Italian privately held biopharma company headquartered in Milan with both specialty pharmaceuticals and biotech products - comparable mid-sized Italian pharma peer serving similar hospital and prescription channels.

TypeDirect peer
Description

Italian privately held pharmaceutical group (Milan) developing, manufacturing and marketing medicinal specialties in women's health, rare disease and specialty therapeutics - similar branded-pharma positioning and scale to Sigma-Tau.

TypeDirect peer
Description

Italian privately held specialty pharmaceutical company focused on pain management and medicinal specialties - directly comparable on business model and Italian specialty-pharma positioning to Sigma-Tau, though smaller in scale.

TypeDirect peer
Description

The Italian pharma company that merged with Sigma-Tau and Biofutura Pharma into Alfasigma on 1 August 2017; a historical direct peer of Sigma-Tau in Italian pharmaceutical manufacturing and distribution.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

sigma-tau

Pharmaceutical Manufacturingsigma-tau.it

Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. was an Italian pharmaceutical group founded in 1957 that manufactured and marketed medicinal specialties. The company ceased independent operations on August 1, 2017, when it merged by incorporation into Alfasigma S.p.A.

What sigma-tau does

Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. was an Italian pharmaceutical group that manufactured and marketed medicinal specialties. Founded in 1957 by Claudio Cavazza, the company operated as a vertically integrated pharmaceutical business organized under Italian law as a società per azioni (S.p.A.), with a workforce of 5,001–10,000 employees. Its core function was the production and distribution of pharmaceutical products under Italian Marketing Authorizations (Autorizzazione all'Immissione in Commercio, AIC), serving the Italian and broader European pharmaceutical market. The company held proprietary marketing authorizations across a portfolio of medicinal specialties accumulated over approximately six decades of operation.

Following decades of independent operation, Sigma-Tau ceased to exist as a separate legal entity on August 1, 2017, through a three-way merger by incorporation into Alfasigma S.p.A., alongside Alfa Wassermann S.p.A. and Biofutura Pharma S.p.A. Alfasigma, headquartered at Via Ragazzi del '99, 5 – 40133 Bologna, Italy (P.IVA 03432221202), assumed all assets, liabilities, and marketing authorizations of the merged entities. The legacy sigma-tau.it domain was retained only to complete the regulatory transfer of AIC holders and was redirected to the Alfasigma corporate site. The legal and administrative headquarters formerly associated with Sigma-Tau in Bologna were transferred to Alfasigma upon completion of the merger.

The company generated revenue through pharmaceutical manufacturing and distribution of its proprietary medicinal specialty portfolio, though no product names, pricing models, distribution channel details, or revenue figures are disclosed in the available source data. All revenue-generating operations and product portfolios are now consolidated under Alfasigma S.p.A., making Sigma-Tau's independent operating history effectively concluded.

sigma-tau firmographics

Firmographics
Name
sigma-tau
Legal name
Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
Website
https://sigma-tau.it
Company type
Private
Founded year
1957
Operating status
Acquired
Headcount range
5,001–10,000 employees
Short description
Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. was an Italian pharmaceutical group founded in 1957 that manufactured and marketed medicinal specialties. The company ceased independent operations on August 1, 2017, when it merged by incorporation into Alfasigma S.p.A.
Ownership category
akta.pro rank

Where sigma-tau is headquartered

Location

Headquarters

HQ city
Vico Nel Lazio
HQ country
Italy
HQ region
Europe

Offices1 record

Markets served

sigma-tau business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

sigma-tau product offering

Product offering

Core offering

Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. was an Italian pharmaceutical company that manufactured and marketed medicinal specialties (specialità medicinali) and pharmaceutical products under registered Marketing Authorizations (AIC). All products, assets, and Marketing Authorizations were transferred to Alfasigma S.p.A. upon the merger effective August 1, 2017.

Product overview

Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. was an Italian pharmaceutical company. As of August 1, 2017, it merged by absorption into Alfasigma S.p.A. along with Alfa Wassermann S.p.A. and Biofutura Pharma S.p.A. The company was involved in the production and distribution of medicinal specialties (specialità medicinali). This legacy page is maintained only to complete the transfer of marketing authorization holders (AIC) to Alfasigma. No specific product names are detailed in the available source data.

Differentiator

Problem solved

Functional benefit

Companies that use sigma-tau

Customer profile

Segments1 record

Ideal customer profiles1 record

sigma-tau technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

sigma-tau partnerships and signals

Strategic signal

Recent moves2 records

Expansion highlights1 record

sigma-tau competitors and assessment

Company assessment

Direct peers

  • Alfasigma S.p.A. Alfasigma is the Italian specialty-pharma group that absorbed Sigma-Tau by merger on 1 August 2017 along with Alfa Wassermann and Biofutura Pharma. It is now the direct continuation of Sigma-Tau's medicinal specialty business and is headquartered in Bologna.
  • Menarini Group: Florence-based privately held Italian pharmaceutical group of comparable mid-large size focused on branded specialty therapeutics, prescription drugs and consumer health - structurally analogous to Sigma-Tau's Italian pharma house positioning.
  • Chiesi Farmaceutici S.p.A. Privately held Italian specialty pharma headquartered in Parma with comparable scale, manufacturing medicinal products for respiratory, neonatology and rare disease - a closely comparable Italian branded-pharma peer to Sigma-Tau.
  • Recordati S.p.A. Listed Italian mid-cap specialty pharmaceutical company headquartered in Milan, focused on branded prescription drugs in cardiovascular, urology and rare diseases - directly comparable in scale, geography and product mix to Sigma-Tau's medicinal specialty business.
  • Zambon S.p.A. Italian privately held pharmaceutical group (Bresso/Milan) producing and marketing branded medicinal specialties across respiratory, pain and CNS - comparable mid-sized Italian specialty pharma peer to Sigma-Tau.
  • Angelini Pharma: Angelini group's pharma division, an Italian privately held branded-pharma manufacturer of medicinal specialties (CNS, pain, infectious disease) - similar scope, scale and Italian distribution model to Sigma-Tau.
  • Dompé Farmaceutici S.p.A. Italian privately held biopharma company headquartered in Milan with both specialty pharmaceuticals and biotech products - comparable mid-sized Italian pharma peer serving similar hospital and prescription channels.
  • Italfarmaco S.p.A. Italian privately held pharmaceutical group (Milan) developing, manufacturing and marketing medicinal specialties in women's health, rare disease and specialty therapeutics - similar branded-pharma positioning and scale to Sigma-Tau.
  • Molteni Farmaceutici: Italian privately held specialty pharmaceutical company focused on pain management and medicinal specialties - directly comparable on business model and Italian specialty-pharma positioning to Sigma-Tau, though smaller in scale.
  • Alfa Wassermann S.p.A. The Italian pharma company that merged with Sigma-Tau and Biofutura Pharma into Alfasigma on 1 August 2017; a historical direct peer of Sigma-Tau in Italian pharmaceutical manufacturing and distribution.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

sigma-tau social profiles

Digital presence

sigma-tau financial estimates

Financial estimate

Revenue estimate

Valuation estimate

sigma-tau leadership team

Management profile

Number of profiles

sigma-tau funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

sigma-tau M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about sigma-tau

What does sigma-tau do?

Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. was an Italian pharmaceutical company that manufactured and marketed medicinal specialties (specialità medicinali) and pharmaceutical products under registered Marketing Authorizations (AIC). All products, assets, and Marketing Authorizations were transferred to Alfasigma S.p.A. upon the merger effective August 1, 2017.

Is sigma-tau a public or private company?

sigma-tau is a private company. It is classified as corporate owned and is currently acquired.

When was sigma-tau founded?

sigma-tau was founded in 1957. It employs 5,001 to 10,000 people.

Where is sigma-tau based?

sigma-tau is headquartered in Vico Nel Lazio, Italy, in the Europe region.

Who are sigma-tau's main competitors?

Direct peers on record are Alfasigma S.p.A., Menarini Group, Chiesi Farmaceutici S.p.A., Recordati S.p.A., Zambon S.p.A., Angelini Pharma, Dompé Farmaceutici S.p.A., Italfarmaco S.p.A., Molteni Farmaceutici and Alfa Wassermann S.p.A..

Does sigma-tau have an API?

No public API is recorded for sigma-tau.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR Newswire15 Years And Going Strong, VSL#3® Maintains Leadership In The Probiotic Medical Food CategorySigma-Tau Pharmaceuticals and VSL Pharmaceuticals are highlighting the 15-year market leadership of VSL#3, a high-potency probiotic medical food clinically proven to manage serious digestive disorders. The brand has been utilized in over 170 studies and remains the most recommended probiotic for conditions such as ulcerative colitis, irritable bowel syndrome, and ileal pouch.GlobeNewswireFennec Announces $5.0 Million Private Placement of Common Shares by Sigma Tau FinanziariaFennec Pharmaceuticals announced a private placement of 2,631,579 common shares for $5 million gross proceeds, to be issued at $1.90 per share. The offering is expected to close in two tranches, with Sigma Tau Finanziaria acquiring 19.30% of the company. Proceeds will fund STS development and working capital.GlobeNewswireSigma-Tau Pharmaceuticals, Inc. Receives Orphan Drug Designation for STP-206 for Prevention of Necrotizing EnterocolitisThe FDA granted orphan drug designation to Sigma-Tau's STP-206, a live biotherapeutic for preventing necrotizing enterocolitis in premature infants under 1,500 grams. The company is conducting a Phase 1b/2a trial, and the designation offers seven-year marketing exclusivity and potential tax credits.GlobeNewswireSigma-Tau Pharmaceuticals, Inc. Receives Orphan Drug Designation for EZN-2279 for Treatment of Adenosine deaminase--Deficient Severe Combined Immunodeficiency DiseaseSigma-Tau Pharmaceuticals received an FDA orphan drug designation for EZN-2279, a PEGylated recombinant version of Adagen, for treating adenosine deaminase-deficient severe combined immunodeficiency. The designation grants seven years of U.S. marketing exclusivity and potential tax credits. The drug is in Phase 3 clinical trials.GlobeNewswireSigma-Tau Pharmaceuticals, Inc. Signs Exclusive Agreement With Crosscare Limited for U.S. Marketing and Distribution License of Colief(R) Infant Drops for the Treatment of Colic-Associated CryingSigma-Tau Pharmaceuticals signed an exclusive U.S. license agreement with Crosscare Limited to market and distribute Colief Infant Drops for colic. The re-launch is planned for August 2014, targeting pharmacy chains and retailers. Financial terms were not disclosed.GlobeNewswireWalgreens Named Exclusive Specialty Pharmacy Provider for Sigma-Tau Pharmaceuticals, Inc.'s Prescription Drugs: Adagen(R), Cystaran(R) and Matulane(R)Walgreens Specialty Pharmacy became the exclusive provider for Sigma-Tau's Adagen, Cystaran, and Matulane, effective July 31, 2014. The drugs are now available at select Walgreens specialty, community, and health system pharmacies. The partnership aims to improve patient access to these medications.GlobeNewswireSigma-Tau Pharmaceuticals, Inc. Announces First Patient Dosed in Phase I/II Clinical Trial of STP206 for Prevention of Necrotizing Enterocolitis in Very Low Birth Weight Premature InfantsSigma-Tau Pharmaceuticals announced the first patient has been dosed in its Phase I/II trial of STP206, a live biotherapeutic for preventing necrotizing enterocolitis in very low birth weight premature infants. NEC affects about 10% of such infants, and no FDA-approved treatment exists. The company aims to become the first FDA-approved live biotherapeutic.GlobeNewswireDave Lemus Promoted to Chief Executive Officer of Sigma-Tau Pharmaceuticals, Inc.Dave Lemus was promoted to Chief Executive Officer of Sigma-Tau Pharmaceuticals, effective immediately, having served as COO since March 2012. The appointment comes as the company expands via commercialization of its internal R&D pipeline and pursuit of externally driven growth opportunities.GlobeNewswireSigma-Tau Pharmaceuticals, Inc. Announces Appointment of New Vice President of Commercial OperationsSigma-Tau Pharmaceuticals appointed Jeff Hackman as Vice President of Commercial Operations, joining its U.S. headquarters in Gaithersburg, Maryland. He previously served as CEO of Intercell AG's U.S. office and held marketing roles at Emergent Biosolutions and MedImmune. The company aims to bring new rare disease drugs to market.GlobeNewswireSigma-Tau Pharmaceuticals, Inc. Announces the U.S. Launch of VSL#3(R) JUNIORSigma-Tau Pharmaceuticals announced the U.S. launch of VSL#3 JUNIOR, a once-a-day probiotic medical food for children with IBS and ulcerative colitis. The product contains 225 billion CFU of eight strains, about 50 times more potent than average probiotics, and is the first studied in a pediatric randomized trial.